Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
An article from
Dive Brief
//
IPO window
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
Parabilis reveals IPO plans the day after Regeneron deal as listings heat up
After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
Another Paragon offshoot chooses reverse merger, this time for migraine drugs
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted…
Parabilis Medicines CEO Mathai Mammen speaks about the biotech's record $670M IPO, its desmoid tumor pipeline and plans beyond…
Parabilis Medicines, the decade-old and well-funded
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug…
Parabilis Medicines priced its upsized IPO at $20 per share, raising $670 million above its expected range, with a $75 million…
If Parabilis follows through with its plans, that would make it one of the largest biotech IPOs of the past few years and the…
